Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCI-LUN-NSC-SBRT-001: SBRT Followed by Chemoradiation and Durvalumab for Locally-Advanced NSCLC
NCT03141359Phase 2Active, not recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- May 2017
- Primary completion
- Jul 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Wake Forest University Health Sciences. Primary endpoint: Number of Participants Progression Free and Surviving at 12 months. Started May 2017; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03141359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03141359.